Pular para o conteúdo principal
Ranking Invest

PTCT - PTC Therapeutics, Inc.

Segmento: HealthcarePTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Análise Ranking Invest

Valor de Mercado
$ 5.18 Bi
IVR
-0.10Índice proprietário de comparação relativa: -0,10.
IVR2
-0.08Leitura proprietária complementar: -8%.
MLL
-0.08Leitura proprietária complementar: -8%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

-$ 165.36 Mi

Dívida Líquida

-$ 458.92 Mi

L4T

-$ 38.38 Mi

MM4T

-13.07%

Indicadores Básicos

ROE

23.21%

Índices de Previsibilidade

Receita Líquida

E0.17

Lucro

F4.60

Margem

E1.50

Índices de Tendência

Receita Líquida

C4.17

Lucro

A9.68

Margem

B7.35

Índices de Endividamento

DIV/PAT

2.78

DIV/L4T

11.96

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.